



## **MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference**

March 14, 2018

WESTLAKE VILLAGE, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that its Chief Executive Officer, Michael Castagna, will present at the Oppenheimer 28<sup>th</sup> Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:20 PM (Eastern Time) at the Westin New York Grand Central.

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at <http://www.mannkindcorp.com>.

### **ABOUT MANNKIND CORPORATION**

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit [www.mannkindcorp.com](http://www.mannkindcorp.com).

### **Company Contact:**

Rose Alinaya  
SVP Investor Relations  
818-661-5000  
[ir@mannkindcorp.com](mailto:ir@mannkindcorp.com)

[Primary Logo](#)

Source: MannKind